Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Shares Repurchased (2023 - 2025)

Dexcom (DXCM) has disclosed Shares Repurchased for 3 consecutive years, with $312.8 million as the latest value for Q4 2025.

  • Quarterly Shares Repurchased changed N/A to $312.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, changed 0.0% year-over-year, with the annual reading at $500.0 million for FY2025, 33.33% down from the prior year.
  • Shares Repurchased for Q4 2025 was $312.8 million at Dexcom, up from $187.2 million in the prior quarter.
  • The five-year high for Shares Repurchased was $750.0 million in Q3 2024, with the low at $187.2 million in Q3 2025.
  • Average Shares Repurchased over 3 years is $437.5 million, with a median of $406.4 million recorded in 2023.
  • Peak annual rise in Shares Repurchased hit 75.04% in 2025, while the deepest fall reached 75.04% in 2025.
  • Over 3 years, Shares Repurchased stood at $500.0 million in 2023, then surged by 50.0% to $750.0 million in 2024, then crashed by 58.29% to $312.8 million in 2025.
  • According to Business Quant data, Shares Repurchased over the past three periods came in at $312.8 million, $187.2 million, and $750.0 million for Q4 2025, Q3 2025, and Q3 2024 respectively.